The Immunotherapy Bridge will start with a Session jointly organized with SITC on TIL Advancements, CAR-T and TILs.
Hence, we will discuss the state of the art of immunotherapy beyond T cells, novel approches for immune monitoring and the organ specific immune response to share what different cancers teach about the general understanding of malignancies.
The final session will be focused on neoadjuvant therapies across cancers.
Immunotherapy Bridge will end with the Great Debate Sessions, in which the most important issues from clinical practice and research will be shown and exhaustively discussed from two different points of view.
GENERAL INFORMATION
WHERE & WHEN
-
Royal Continental Hotel Naples,
Italy - December 4th - 5th 2024
CALL FOR ABSTRACT
TOPICS
- TIL Advancements: CAR-T and TILs
Immunotherapy beyond T Cells and - Immunotherapy beyond classical T Cells
- Immune Monitoring: Novel Platforms and Approaches
- Organ Specific Immune Response
- Neoadjuvant Therapy across Cancers
PRESIDENCY
Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione “G. Pascale”, Naples, Italy
Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; President of Society for Immunotherapy of Cancer (SITC)
Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US
Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US
PRESIDENCY
Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute IRCCS “Fondazione G. Pascale”, Naples, Italycierto
Professor of Medicine, Director of Translational Immunotherapy for the Women’s Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women’s Hospital, Pittsburgh, PA, US
Bernard A. Fox Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center – Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, US
Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US
SCIENTIFIC BOARD
Sanjiv S. Agarwala
Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US
Paolo A. Ascierto
Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione “G. Pascale”, Naples, Italy
Carlo Bifulco
Chief Medical Officer, Providence Genomics, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US
Christian Blank
Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
Elizabeth M. Burton
Executive Director, Translational Research Initiative Development, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US
Lisa H. Butterfield
Adjunct Professor of Microbiology and Immunology, University of California San Francisco, CA, US
Corrado Caracò
Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS Fondazione “G. Pascale”, Naples, Italy
Mary Dean
Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US
Sandra Demaria
Professor of Radiation Oncology, Professor of Pathology and Laboratory Medicine Weill Cornell Medicine, New York, NY, US
Reinhard Dummer
Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland
Alexander M.M. Eggermont
Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical&Translational Immunotherapy, Utrecht University, Utrecht, Netherlands
Leisha A. Emens
Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; President of Society for Immunotherapy of Cancer (SITC)
Bernard A. Fox
Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US
Jerome Galon
Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France
Claus Garbe
Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen,Germany
Jeffrey E. Gershenwald
Dr. John M. Skibber Endowed Professor of Surgery, Department of Surgical Oncology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA
Omid Hamid
Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US
Samir N. Khleif
Director of Center for Immunology and Immunotherapy, Director of The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, US
Giuseppe Masucci
Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden
Olivier Michielin
Full Professor, Chair of Oncology Department and Precision Oncology Service, Geneva University Hospital, Geneva; Co-Director of the Swiss Cancer Center Léman, Agora – Lausanne, Switzerland
Iman Osman
Rudolf Baer Professor of DermatologyProfessor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US
Giuseppe Palmieri
Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy
Michael A. Postow
Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US
Igor Puzanov
Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US
Dirk Schadendorf
Director of the Department of Dermatology, University Hospital Essen, Essen, Germany
Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US
Tara Withington
Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US
